FDA approves Novo Nordisk’s Novoeight for hemophilia A
BAGSVÆRD, Denmark — The Food and Drug Administration has approved a new drug made by Novo Nordisk for treating hemophilia A, the Danish drug maker said.
Novo Nordisk announced the approval of Novoeight (turoctocog alfa), a recombinant coagulation factor VIII, for adults and children with hemophilia, a disease caused by factor VIII deficiency that results in uncontrollable bleeding.
"The approval of Novoeight marks an important step in offering a new alternative for people with hemophilia A and demonstrates our commitment to hemophilia," Novo Nordisk chief science officer and EVP Mads Krogsgaard Thomsen said.
The company plans to launch the drug in April 2015 and will launch it with a newly introduced prefilled injector called MixPro.
WomenHeart announces Science & Leadership Symposium graduates for 2013
WASHINGTON — Nearly two dozen women with heart disease will educate their communities about heart disease in women.
WomenHeart, a group focused on heart disease in women, said 23 women had graduated from the WomenHeart Science & Leadership Symposium at the Mayo Clinic in Rochester, Minn., to become WomenHeart Champions. The symposium is sponsored by the Medtronic Foundation, Boston Scientific, Edwards Lifesciences, Gilead, Astellas Pharma, AstraZeneca, Novartis, St. Jude Medical Foundation, Bristol-Myers Squibb and Genentech. The 2013 graduates join 628 graduates from previous years to become the "boots on the ground" to spread awareness about heart disease, the organization said; the symposium started in 2002.
"Heart disease can be a very emotionally and physically isolating condition for women," WomenHeart CEO Lisa Tate said. "WomenHeart Champions and the support networks that they build enable women to have the peer-to-peer support they need to make the lifestyle changes necessary to live a heart-healthy life."
Heart disease is the leading cause of death in women, and more women than men have died from heart disease every year since 1984, according to the group.
Reports: Oregon Board of Pharmacy head to step down
NEW YORK — The executive director of the Oregon Board of Pharmacy is leaving, according to published reports.
The Lund Report, an online publication that covers Oregon’s healthcare system, reported that Gary Schnabel was stepping down to pursue "other interests." Schnabel turned 65 years old this month and has lead the board for 19 years.
Highlights from Schnabel’s career include being invited by former Sen. Gordon Smith, R-Ore., in January 2005 to testify before Congress on the state’s experience with selling drugs online, just before the confirmation of then-Secretary of State Condoleezza Rice.
According to The Lund Report, Schnabel intends to work as a consultant, doing on-site inspections of compounding pharmacies for the National Association of Boards of Pharmacy and consulting with drug companies.